Anticipation of rising drug prices drives gains for Novo Nordisk and Eli Lilly
- Health-care companies rise on anticipation of rising drug prices amid U.S. pharmaceutical shortages
- Novo Nordisk and Eli Lilly see blockbuster gains, up by more than 22%
- Federal Trade Commission launches probe into recent shortages of chemotherapies and other drugs
- Shares of WuXi family of biotech and research companies extend losses amid concerns of U.S. lawmakers
Health-care companies experienced a sharp rise in stock prices as investors anticipated rising drug prices due to ongoing pharmaceutical shortages in the U.S. Novo Nordisk and Eli Lilly, in particular, saw blockbuster gains, with both companies’ stocks increasing by more than 22% in the first six weeks of the year. The Federal Trade Commission has also launched a probe into the recent shortages of chemotherapies and other drugs, investigating the role played by companies involved in the purchase and distribution of medicines to U.S. hospitals. Additionally, shares of the WuXi family of biotech and research companies have been declining due to concerns raised by U.S. lawmakers regarding alleged ties to the Chinese military and the Chinese Communist Party.
Public Companies: Novo Nordisk (N/A), Eli Lilly (N/A), WuXi (N/A)
Private Companies:
Key People:
Factuality Level: 7
Justification: The article provides information about the rise in health-care companies due to anticipation of rising drug prices and the investigation by the Federal Trade Commission into drug shortages. It also mentions the losses of the WuXi family of companies due to concerns over alleged ties to the Chinese military and Communist Party. However, the article lacks specific details and context about the reasons behind the rise in drug prices and the investigation, which could affect the overall factuality level.
Noise Level: 3
Justification: The article provides relevant information about the rise in health-care companies due to anticipated rising drug prices and the investigation by the Federal Trade Commission into drug shortages. However, it also includes unrelated information about the WuXi family of biotech companies and their alleged ties to the Chinese military and Communist Party, which is not directly related to the main topic.
Financial Relevance: Yes
Financial Markets Impacted: Health-care companies
Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article discusses the rise in health-care companies’ stock prices due to anticipation of rising drug prices amid U.S. pharmaceutical shortages. It also mentions the Federal Trade Commission launching a probe into recent shortages of chemotherapies and other drugs. However, there is no mention of any extreme event.
www.marketwatch.com 
